骨形态发生蛋白联合甲状旁腺素评估血液透析联合血液灌流对血液透析肾性骨病患者疗效的效能  

Efficacy of bone morphogenetic protein combined with parathyroid hormone in the evaluation of effect of hemodialysis combined with hemoperfusion on patients with renal osteodystrophy after hemodialysis

作　　者：叶晓燕[1] 于金兰[1] 宋新霞[1] 杨玲[1] 李俊娟 Ye Xiaoyan;Yu Jinlan;Song Xinxia;Yang Ling;Li Junjuan(Hemodialysis Department,Yantai Laiyang Central Hospital,Yantai 265200,China)

机构地区：[1]烟台市莱阳中心医院血液透析科,烟台265200

出　　处：《国际医药卫生导报》2023年第11期1518-1522,共5页International Medicine and Health Guidance News

基　　金：山东省自然科学基金面上项目(ZR2020MH200)。

摘　　要：目的分析骨形态发生蛋白(BMP)、甲状旁腺激素(PTH)评估血液透析联合血液灌流对血液透析肾性骨病患者疗效的效能。方法回顾性选取2019年1月至2021年6月烟台市莱阳中心医院收治的120例血液透析肾性骨病患者为研究对象,其中男63例,女57例,年龄20.52~78.96岁,经血液透析联合血液灌流治疗,收集患者BMP、PTH等临床资料,随访1年。统计随访期间血液透析联合血液灌流对血液透析肾性骨病患者疗效情况,分析血液透析联合血液灌流治疗后血液透析肾性骨病患者疗效的影响因素,分析BMP与PTH评估血液透析联合血液灌流治疗后血液透析肾性骨病患者无效的价值。采用独立样本t检验、χ^(2)检验、多因素logistic回归分析。结果120例行血液透析联合血液灌流治疗后血液透析肾性骨病患者,有20例(16.67%)无效,其余100例(83.33%)有效。无效组与有效组性别、年龄、高血压、高血脂、糖尿病、吸烟、饮酒、收缩压、白蛋白对比,差异均无统计学意义(均P>0.05);无效组BMP、PTH高于有效组(t=3.538、19.018,均P<0.001)。多因素分析显示BMP、PTH水平是血液透析联合血液灌流治疗后血液透析肾性骨病患者疗效的影响因素(OR=2.849,P=0.032;OR=2.770,P<0.001)。受试者工作特征曲线(ROC)分析结果显示,BMP、PTH及二者联合评估血液透析联合血液灌流治疗后血液透析肾性骨病患者无效的灵敏度分别为73.91%、73.91%、86.95%,曲线下面积(AUC)分别为0.763、0.758、0.860;BMP联合PTH的灵敏度高于BMP、PTH单一评估(均P<0.001)。结论BMP、PTH水平与血液透析联合血液灌流治疗后血液透析患者并发肾性骨病有关,BMP处于高水平时肾性骨病发生风险更高,二者联合评估血液透析联合血液灌流治疗后血液透析患者并发肾性骨病效能较高。Objective To analyze the efficacy of bone morphogenetic protein(BMP)combined with parathyroid hormone(PTH)in the evaluation of effect of hemodialysis combined with hemoperfusion on patients with renal osteodystrophy after hemodialysis.Methods A total of 120 patients with renal osteodystrophy after hemodialysis admitted to Yantai Laiyang Central Hospital from January 2019 to June 2021 were retrospectively selected as the study objects,including 63 males and 57 females,aged 20.52-78.96 years.After hemodialysis combined with hemoperfusion,clinical data such as BMP and PTH were collected and followed up for 1 year.The curative effect of hemodialysis combined with hemoperfusion on patients with renal osteodystrophy after hemodialysis during the follow-up period were recorded.The factors that affected the curative effect of patients with renal osteodystrophy after hemodialysis after hemodialysis combined with hemoperfusion treatment were analyzed.The values of BMP and PTH in evaluating the ineffectiveness of patients with renal osteodystrophy after hemodialysis after hemodialysis combined with hemoperfusion treatment were analyzed.Independent sample t test,χ^(2) test,and multiple logistic regression analysis were used.Results Among the 120 patients with renal osteodystrophy after hemodialysis,20 patients(16.67%)were ineffective after hemodialysis combined with hemoperfusion treatment,and the remaining 100 patients(83.33%)were effective.There were no statistically significant differences in the gender,age,hypertension,hyperlipidemia,diabetes,smoking,drinking,systolic blood pressure,and albumin between the ineffective and effective groups(all P>0.05).The levels of BMP and PTH in the ineffective group were higher than those in the effective group(t=3.538 and 19.018,both P<0.001).Multifactor analysis showed that BMP and PTH were the factors affecting the efficacy of patients with renal osteodystrophy after hemodialysis after hemodialysis combined with hemoperfusion treatment(OR=2.849,P=0.032;OR=2.770,P<0.001).The receiver

关 键 词：血液透析 血液灌流 肾性骨病 骨形态发生蛋白 甲状旁腺激素 高血脂 糖尿病 

分 类 号：R692.5[医药卫生—泌尿科学] R68[医药卫生—外科学]